what does the future hold for lag-3 as a novel target in melanoma?
Published 1 year ago • 106 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
0:36
lag-3: a promising biomarker in cancer
-
0:58
the future of immune checkpoint inhibition in melanoma
-
16:13
depicting lag3: exploring a new target in metastatic melanoma
-
1:28
triple pd-1, lag-3 and tim-3 inhibition in solid tumors
-
6:00
future directions: targeting lag-3 in melanoma treatment
-
3:10
the future of immunotherapy in melanoma
-
7:02
nivo lag-3 antibody succeeds in advanced melanoma
-
2:59
lag-3 antibody combination in immunotherapy-treated melanoma
-
1:05:28
galvanizing your health: why you need zinc
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
13:09
jen's story - touched by melanoma stages 3 & 4
-
2:33
combining an anti-lag-3 antibody with nivolumab in melanoma
-
2:49
emerging melanoma therapeutics: ido1, lag-3 & hdac inhibitors
-
6:17
relativity-047: relatlimab, an anti-lag-3 antibody nivolumab in first-line advanced melanoma
-
1:06
current and future treatment options for uveal melanoma
-
1:13
clinical trials investigating the treatment of melanoma
-
2:31
the synergy of lag-3 and other immune checkpoint pathways in cancer
-
5:03
lag3 inhibitor
-
1:32
novel treatment combinations for flt3-mutated aml
-
3:40
developments in the management of stage iii melanoma
-
1:03
what can be achieved with triple combination therapy phase i trial for metastatic melanoma